Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella (ellipseII)

H

HRA Pharma

Status

Completed

Conditions

Emergency Contraception

Treatments

Drug: ella

Study type

Observational

Funder types

Industry

Identifiers

NCT01569737

2914-012

Details and patient eligibility

About

The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.

Enrollment

98 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Pregnant women, exposed to ella during the menstrual cycle in which the pregnancy started (treatment failure) or at any time during pregnancy (inadvertent exposure during pregnancy)
Adolescents and/or adults in the USA, depending on the respective State law